The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
£1.431m in the bank, should they take their options. They appeared great at the time.
If they spent that money now, they would get 3.6m shares.
Admittedly the option come risk free.
We can moan again in 12 months when they take their options and we are at£1.50+, but it’s old news!
BB
From Seeking alpha link:
'The Company also earlier this month filed a form F-3 registration statement with the SEC to raise up to an aggregate of $150 million from sale of various securities including American Depositary Shares (ADSs).'
My previous post: The above supporting my theory - If legal????
21m ADR's traded on the Nasdaq on 23 March??
Thats 10+ shares per ADR (over 210m shares traded) - Apparently 7m were short with a sp ranging from $5.50 to $8.80, now at $4.83.
4D has a facility on the Nasdaq to issue shares as required. Could they have arranged with some II's to raise at $6. The II's short, then receive their allocation, thus closing the short - make money both ways - Announce funding news and up we go - fully funded.
Probably a pipe dream, but 21m ADR's is more shares than the company has in issue, by a fair way.
Any ideas?
BB
https://www.proactiveinvestors.co.uk/companies/news/978521/4d-pharma-has-a-busy-year-ahead-after-a-successful-12-months-of-clinical-research-978521.html
The update was provided alongside prelims which showed the drug developer posted a £26.1mln operating loss in the year to 31 December 2021 after it spent £19.8mln on research and development. The deficit grew to £54.7mln after accounting for the fair value of shares and warrants. As at the year-end it had £15.5mln in the bank.
BB
Thats 10+ shares per ADR (over 210m shares traded) - Apparently 7m were short with a sp ranging from $5.50 to $8.80, now at $4.83.
4D has a facility on the Nasdaq to issue shares as required. Could they have arranged with some II's to raise at $6. The II's short, then receive their allocation, thus closing the short - make money both ways - Announce funding news and up we go - fully funded.
Probably a pipe dream, but 21m ADR's is more shares than the company has in issue, by a fair way.
Any ideas?
BB
I'll buy up some of the T10 holders shares.
Excellent prospects.
BB
Usually around 500k shares / month on Nasdaq
RNS day in March 21m shares.
A lot of new holders
BB
RG
Luckily you’re out & won’t need to worry about the next RNS.
I’m in & remarkably, I sleep really well.
BB
SK
Spread the happiness.
BB
Wolfiebill
I wish you had replied to the next thread.
This appears more of a legal trial. Apologies, predictive text.
BB
Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody’.
Dr. Kunwar Shailubhai, Chief Executive Officer and Chief Scientific Officer of Tiziana, commented, "The oral route of administration is the preferred route for all pharmaceuticals. The “Holy Grail” for biologics is the “switch” from parenteral (IV, SC) to oral administration as it is the most economical, non-invasive, and convenient route with respect to patient's quality of life and compliance. We have developed proprietary formulation technologies, enabling oral, nasal, and inhalation routes for administration of antibodies, to facilitate local action at the respective target sites. We believe this Phase 1b study is a logical first step towards the clinical validation of oral immunotherapy with foralumab capsules, to provide local action rather than systemic delivery, for CD treatment.”
Howard Weiner, M.D., Director of the Multiple Sclerosis Program at the Brigham and Women’s Hospital (BWH) and Chairman of Tiziana's Scientific Advisory Board, commented, “Treatment with orally or nasally administered foralumab is a novel physiological approach to stimulate the mucosal immune system to induce disease-modifying benefits while minimizing the toxicities that are commonly associated with the traditional intravenous or subcutaneous immunotherapies. In this regard, the first validation of our innovative approach came from our recently reported clinical results showing positive clinical benefits in a patient with secondary progressive multiple sclerosis (SPMS), who was treated for 6 months with intranasally administered foralumab3."
Gla
Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody’.
Dr. Kunwar Shailubhai, Chief Executive Officer and Chief Scientific Officer of Tiziana, commented, "The oral route of administration is the preferred route for all pharmaceuticals. The “Holy Grail” for biologics is the “switch” from parenteral (IV, SC) to oral administration as it is the most economical, non-invasive, and convenient route with respect to patient's quality of life and compliance. We have developed proprietary formulation technologies, enabling oral, nasal, and inhalation routes for administration of antibodies, to facilitate local action at the respective target sites. We believe this Phase 1b study is a logical first step towards the clinical validation of oral immunotherapy with foralumab capsules, to provide local action rather than systemic delivery, for CD treatment.”
Howard Weiner, M.D., Director of the Multiple Sclerosis Program at the Brigham and Women’s Hospital (BWH) and Chairman of Tiziana's Scientific Advisory Board, commented, “Treatment with orally or nasally administered foralumab is a novel physiological approach to stimulate the mucosal immune system to induce disease-modifying benefits while minimizing the toxicities that are commonly associated with the traditional intravenous or subcutaneous immunotherapies. In this regard, the first validation of our innovative approach came from our recently reported clinical results showing positive clinical benefits in a patient with secondary progressive multiple sclerosis (SPMS), who was treated for 6 months with intranasally administered foralumab3."
Gla
BB
The daily RSI has now settled back a bit. Hopefully we can move on.
BB
I started to accumulate 4d in Dec at 57p. Back then it had more risk. I now hold a reasonable chunk and can buy at 55p following a great RNS. 4d is risk free at this price. Accumulation by the big boys now. While the impatient and the traders sell up.
Gla
BB
Denny11: How does that help them raise money? Surely that'll be done by a further share issue?
The higher the listing price the better for us.
The higher the price, the less dilution for us.
Hope that helps!
BB
Cloudy
That would be great.
BB
SK
I have absolutely no idea!
People have mentioned, £280m from a previous analysts note - 10% of $2.8b buyout of the competitor & we are 40% better - but not out there proving it! - Don't shoot the messenger.
Initial mcap for 10m shares at $5 could be $50m, but no cash.
Could we raise at $5 and have 50m shares with $200m in the bank to progress. That initial $50m valuation would rise substantially. Would someone buy that down the line for $1b when it is up & running with proof of success in a few hospitals, or do we wait longer for a higher bid but more dilution. Too many permutations.
It will be worth something shortly - but what??
Sorry - No help at all
BB
PG
Thanks for the info. SNG looked to be bucking the Pharma down trend for such a long time. Best of luck to your SNG investment.
I'm sticking with 4D & TLSA, that's enough pharma risk for me!
BB
That is on top of the recent drop.
The Pharma world allows for massive gains, but with that massive falls.
Let s hope we have a positive update here (Apologies to any dual SNG/DDDD holders, not rubbing anyones nose in it).
BB
My son's SIPP- secure message today:
We wrote to you in September 2021 about Tiziana Life Sciences plan to convert to a Bermuda incorporated company with its shares listed on the NASDAQ stock market in the US.
This has completed and you’ve been given 1 new Bermuda incorporated share for every 2 shares held previously.
The new shares were originally issued outside of the UK settlement system (Crest) meaning we had to hold the shares with our global custodian, HSBC.
However, the shares are now eligible to be held in the UK in Crest. We have therefore automatically moved them into Crest meaning you can now trade them online and won’t have to pay the additional transaction charge referred to in our original correspondence.
Your SIPP was updated on 9 March 2022 on the following basis:'
BB
Big thumbs up to that.
BB